전립선암 진단 시장 규모, 점유율, 성장 분석 : 검사 유형별, 기술별, 암 유형별, 최종사용자별, 용도별, 지역별 - 산업 예측(2026-2033년)

Global Prostate Cancer Diagnostics Market size was valued at USD 9.1 Billion in 2024 and is poised to grow from USD 9.69 Billion in 2025 to USD 16.04 Billion by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).

The global prostate cancer diagnostics market is significantly influenced by the increasing prevalence of prostate cancer, alongside advancements in screening programs and technological innovations. This market encompasses a variety of tools, including biochemical assays, imaging techniques, and biopsy systems that utilize molecular classifiers for precise disease detection and characterization. The transition from broad PSA screening to targeted approaches, such as multiparametric MRI and genomic testing, has prompted investments in noninvasive diagnostic tools. Enhanced clinical utility, supported by substantial evidence and reimbursement frameworks, is fostering adoption and scaling of these innovations. Notable trends include the replacement of traditional imaging methods with more effective technologies, leading to improved risk stratification and operational efficiencies. Consequently, opportunities are growing in integrated care pathways and in emerging regions with unmet diagnostic needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Prostate Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Prostate Cancer Diagnostics Market Segments Analysis

Global prostate cancer diagnostics market is segmented by test type, technology, cancer type, end user, application and region. Based on test type, the market is segmented into preliminary tests, confirmatory tests, PSA tests, free PSA tests, total PSA tests, PCA3 tests, biopsy tests and imaging tests. Based on technology, the market is segmented into molecular diagnostics, immunoassays, next-generation sequencing (NGS), PCR-based testing, AI-based imaging diagnostics and liquid biopsy. Based on cancer type, the market is segmented into adenocarcinoma, small cell carcinoma, transitional cell carcinoma and other rare prostate cancer types. Based on end user, the market is segmented into hospitals, diagnostic laboratories, cancer research institutes, specialty clinics, outpatient facilities and others. Based on application, the market is segmented into screening, risk assessment, early detection, tumor staging, monitoring & recurrence detection and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Prostate Cancer Diagnostics Market

The Global Prostate Cancer Diagnostics market is significantly driven by the advancements in molecular diagnostics, which provide greater specificity and improved characterization of prostate cancer biology. This enhanced accuracy bolsters clinicians' confidence in making diagnostic decisions and facilitates personalized treatment strategies. As more healthcare providers and patients recognize the benefits of molecular testing, the demand for assays that differentiate between aggressive and indolent prostate cancer intensifies. In response, laboratories and diagnostic firms are expanding their product offerings and incorporating molecular assays into standard clinical practices. This trend not only supports market growth but also attracts investments in complementary technologies and innovative commercial approaches.

Restraints in the Global Prostate Cancer Diagnostics Market

The Global Prostate Cancer Diagnostics market faces challenges due to the complex and varied regulatory requirements in different regions, which hinder the swift commercialization of new diagnostic tests. The necessity for comprehensive clinical validation and thorough documentation often leads to delays in market entry and amplifies initial development costs. Manufacturers encounter diverse evidentiary standards and approval processes, slowing the delivery of innovations to clinicians and patients. This regulatory ambiguity can deter investment and strategic growth, prompting companies to focus on markets with more straightforward procedures, ultimately restricting the wider global adoption of advanced diagnostic technologies.

Market Trends of the Global Prostate Cancer Diagnostics Market

The Global Prostate Cancer Diagnostics market is witnessing a notable trend toward the adoption of noninvasive testing methods, reflecting a shift in clinician and patient preferences for convenience and comfort. Innovative blood and urine biomarker assays, complemented by advanced imaging techniques, are increasingly integrated earlier in patient care pathways to enhance risk stratification and reduce the reliance on invasive procedures. In response, diagnostic companies are strategically developing products that emphasize clinical utility and patient adherence while ensuring ease of implementation in various healthcare settings. This trend is fostering the expansion of noninvasive diagnostics across primary and specialty care networks, enabling scalable solutions for improved patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Prostate Cancer Diagnostics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Preliminary Tests
• Confirmatory Tests
• PSA Tests
• Free PSA Tests
• Total PSA Tests
• PCA3 Tests
• Biopsy Tests
• Imaging Tests

Global Prostate Cancer Diagnostics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Molecular Diagnostics
• Immunoassays
• Next-generation Sequencing (NGS)
• PCR-based Testing
• AI-based Imaging Diagnostics
• Liquid Biopsy

Global Prostate Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Adenocarcinoma
• Small Cell Carcinoma
• Transitional Cell Carcinoma
• Other Rare Prostate Cancer Types

Global Prostate Cancer Diagnostics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes
• Specialty Clinics
• Outpatient Facilities
• Others

Global Prostate Cancer Diagnostics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Screening
• Risk Assessment
• Early Detection
• Tumor Staging
• Monitoring & Recurrence Detection
• Others

Global Prostate Cancer Diagnostics Market Size & CAGR (2026-2033)

• North America (Test Type, Technology, Cancer Type, End User, Application)
  • US
  • Canada
• Europe (Test Type, Technology, Cancer Type, End User, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Technology, Cancer Type, End User, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Technology, Cancer Type, End User, Application)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Technology, Cancer Type, End User, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MDxHealth SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPKO Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations